James Potter, the executive director at Coalition for Healthcare Communication (CHC), has rose-colored glasses on. | In a ...

As Robert F. Kennedy Jr.’s revamped Centers for Disease Control and Prevention (CDC) vaccine advisory panel gears up to meet ...

The resulting report, published this week ahead of Swoop’s presentation at the Fierce Pharma Week conference in Philadelphia, ...

While Gilead Sciences previously ponied up hundreds of millions of dollars to resolve kickback allegations related to its HIV business, the company this week triumphed over a whistleblower lawsuit | A ...

It was another swing and a miss for the biopharma industry on Thursday, when a federal appeals court in Philadelphia ...

With Pfizer discontinuing Beqvez and BioMarin scaling back the commercial focus of Roctavian, the curative promise of ...

FDA leaders under President Donald Trump are moving to abandon a decades-old policy of asking outside experts to review drug ...

The Trump administration is reportedly weighing an executive order to limit drug licensing deals with Chinese biotechs. | The ...

The changes come five weeks into the tenure of new CEO Maziar Mike Doustdar. Doustdar was tapped to replace Novo's previous ...

AbbVie has settled with each of the drugmakers that have filed for FDA approval of Rinvoq generics, preventing copycat ...

After years of regulatory struggles for Intercept Pharmaceuticals and its liver disease drug Ocaliva (obeticholic acid), the ...

Approved 15 months ago as a pneumococcal disease vaccine for adults—and billed as the first shot designed for seniors—Merck’s ...